WHO ICTRP trial
A randomized, double-blind, placebo-controlled, three-period two treatment…
NL-OMON55004 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON55004 |
|---|---|
| Public title | A randomized, double-blind, placebo-controlled, three-period two treatment incomplete-block crossover study to investigate the effects of intravenous GSK3858279 on a battery of evoked pain tests in healthy participants. |
| Scientific title | A randomized, double-blind, placebo-controlled, three-period two treatment incomplete-block crossover study to investigate the effects of intravenous GSK3858279 on a battery of evoked pain tests in healthy participants. - GSK3858279 vs PBO, Phase 1, Pain Tests, PK and Target Engagement in HV |
| Primary sponsor | GlaxoSmithKline |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Countries | The Netherlands |
| Conditions | Chronic pain diseases. Chronic pain diseases;Chronic pain diseases |
| Interventions | GSK3858279, 3 mg/kg. single dose, once per study period or Placebo single dose, once per study period. Participants will receive up to 2 single doses of GSK3858279. ;Cross over;Intravenous;Pain |
| Registration date | Jun 9, 2021 |
| Target size | 30 |
| Secondary IDs | 2019-002609-23;NL71013.056.19 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- Yes Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: